November 20, 2019 / 12:01 AM / 16 days ago

Fed Circuit sides with Mylan in Sanofi insulin patent fight

A federal appeals court on Tuesday upheld a U.S. Patent and Trademark Office ruling that boosted Mylan’s ongoing effort to launch a generic version of the blockbuster Sanofi diabetes treatment Lantus.

Affirming the PTO’s Patent Trial and Appeal Board, the Federal Circuit said in a 2-1 decision that two Sanofi patents on Lantus were invalid on obviousness grounds.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below